5-Amino-1MQ vs Omentin-1
Head-to-head comparison of 5-Amino-1MQ (5-Amino-1-methylquinolinium) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | 5-Amino-1MQ | Omentin-1 |
|---|---|---|
| Category | Weight Management | Diabetes & Metabolic |
| Full Name | 5-Amino-1-methylquinolinium | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 178.23 g/mol | ~35 kDa |
| Half-Life | ~6 hours | hours |
| Amino Acids | Small molecule | 313 |
| Typical Dose | — | No approved human dose; research use only |
| Route | — | IV|SC |
| Purity | >98% | ≥98% |
| Studies Count | 28 | 82 |
| Research Status | Active Research | Pre-clinical |
5-Amino-1MQ Benefits
- ✓Reduces body fat without appetite changes, lowers cholesterol, increases NAD+ levels, improves metabolic efficiency, supports cellular energy production
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
5-Amino-1MQ Dosing
Research doses: 50-150 mg orally daily. Often cycled 8-12 weeks on, 4 weeks off. Best taken in the morning.
Omentin-1 Dosing
not established|not established
5-Amino-1MQ Side Effects
- ⚠Generally well-tolerated in preclinical models. Potential mild GI discomfort and headache. Long-term human safety data is limited.
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
5-Amino-1MQ
Studies in diet-induced obese mice showed significant reductions in body weight, white adipose tissue mass, and cholesterol levels without changes in food intake. Works by inhibiting NNMT enzyme to increase NAD+ and activate sirtuins.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.